These medtech companies raised the most VC last year

Share

8 (tied). ImmusanT

Cambridge, Mass.
Venture capital raised: $40 million

immusant-logo

ImmusanT raised $40 million in venture capital during its expansion stage of development in the fourth quarter of 2017, according to the MoneyTree Report. This is the company’s third investment sequence and investors include ARCH Venture Partners and Vatera Healthcare Partners.

ImmusanT is working to increase tolerance to gluten in people who have celiac disease. The company is improving diagnosis and treatment by harnessing new discoveries in immunology. ImmusanT is developing a therapeutic vaccine for celiac disease called Nexvax2, as well as a diagnostic and monitoring tool to improve management of the disease.

Next >>

Join the Best Minds in MedTech at DeviceTalks Minnesota!

textadimage This year’s DeviceTalks Minnesota features four tracks packed with expertly curated content created by the industry for the industry.

ECO-SYSTEM TRACK: focuses on issues impacting medtech companies across Minnesota and beyond. TECHNOLOGY TRACK: drills down on the hottest new tech that is changing medtech. REGULATORY 201 and CLINCAL 201 TRACKS: Hosted by Medical Alley and focuses on the most important trends in regulatory and clinical development.

Take a look at our full agenda.

Use the code "TRACKS" to save 15% on the cost of registration. 

REGISTER TODAY

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Speak Your Mind

*